Cara Therapeutics, Inc. (NASDAQ:CARA) Q4 2022 Earnings Call Transcript

So that’s why they got the third year. So, to answer your question, I would say later next year, at the end of next year, probably the end of 2024 would be the best time to kind of calculate to see what sort of funding would be required for KORSUVA.

Sumant Kulkarni: And then just the last one on those lines, is this instability or volatility in demand an advantage or disadvantage when it comes to TDAPA extension?

Chris Posner: Well, again, I could only look at what parsabiv — they use it as an advantage to get a third year, right, so say in the first six months of a launch or it’s not steady state? That’s again, I would say more of a personal opinion. I mean, I don’t have many data points to look at other than that.

Operator: Thank you. This concludes the Q&A session. I’d now like to turn the call back over to Chris for any closing remarks.

Chris Posner: Yes. So, I’d like to thank everyone for joining us this afternoon. And we look forward to providing updates in the coming quarter. Thank you very much.

Operator: Thank you. This concludes today’s conference call. Thank you for participating. You may now disconnect.